Ligand Pharmaceuticals (LGND) free cash flow

Free cash flow · fiscal 2025
$38.05M

Ligand Pharmaceuticals (LGND) generated free cash flow of $38.05M in fiscal 2025 (the year ended December 31, 2025). That is 50.9% lower than the $77.41M of fiscal 2024. Figures as of 18 Nov 2026, 12:20 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$38.05M
Change on fiscal 2024
−50.9%
Growth, 5 years
−5.4% a year
Growth, 10 years
−0.9% a year
Highest on record
$193.17Mfiscal 2018
Lowest on record
-$34.32Mfiscal 2009
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Ligand Pharmaceuticals free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow shrank at a compound 5.4% a year; over ten years the rate was −0.9% a year. Across the 17 fiscal years on record (2009–2025), the highest was $193.17M in fiscal 2018 and the lowest -$34.32M in fiscal 2009.

History · 17 fiscal years

Free cash flow by fiscal year

Ligand Pharmaceuticals free cash flow, year by year

Ligand Pharmaceuticals (LGND) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$38.05M 50.9% down
2024$77.41M—
2023-$4.27M 103.6% down
2022$119.93M 71.2% up
2021$70.04M 39.7% up
2020$50.13M—
2019-$31.89M 116.5% down
2018$193.17M 123.5% up
2017$86.41M 46.8% up
2016$58.88M 41.4% up
2015$41.63M 102.5% up
2014$20.56M 1.2% up
2013$20.31M—
2012-$434.00K—
2011-$1.25M—
2010-$27.14M—
2009-$34.32M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Ligand Pharmaceuticals and comparable companies
CompanyFree cash flowFiscal year
RadNet RDNT$85.57M2025
Belite Bio BLTE-$37.17M2025
Ligand Pharmaceuticals LGND$38.05M2025
Scholar Rock Holding SRRK-$300.64M2025
Teleflex TFX$245.44M2025
Mirum Pharmaceuticals MIRM$54.87M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on LGND

Ligand Pharmaceuticals, figure by figure

Ligand Pharmaceuticals (LGND) overview: price, valuation and scorecardAll health care companies by market value

Ligand Pharmaceuticals free cash flow: questions and answers

What is Ligand Pharmaceuticals's free cash flow?

Ligand Pharmaceuticals (LGND) generated free cash flow of $38.05M in fiscal 2025 (the year ended December 31, 2025). That is 50.9% lower than the $77.41M of fiscal 2024.

What is the growth rate of Ligand Pharmaceuticals's free cash flow?

Over the five fiscal years to 2025 free cash flow shrank at a compound 5.4% a year; over ten years the rate was −0.9% a year.

What are the highest and lowest free cash flow figures on record for Ligand Pharmaceuticals?

Across the 17 fiscal years on record (2009–2025), the highest was $193.17M in fiscal 2018 and the lowest -$34.32M in fiscal 2009.

How is Ligand Pharmaceuticals's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Ligand Pharmaceuticals it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ligand Pharmaceuticals (LGND) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/LGND/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.